MedTrace Logo

Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections

NCT05429450 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-09-21

No results posted yet for this study

Summary

The study objective is to investigate the efficacy and safety of periocular injections of methotrexate in management of patients with active moderate to severe thyroid associated orbitopathy in comparison to periocular injections of triamcinolone acetonide.

Conditions

  • Thyroid Associated Orbitopathy

Interventions

DRUG

Methotrexate

Three periocular injections of methotrexate at week 0, week 3 and week 6.

DRUG

Triamcinolone Acetonide

Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Haytham E. Nasr · Cairo University

  • Rania A. El Essawy · Cairo University

  • Kareem B. Elessawy · Cairo University

  • Islam Y. Swaify · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-07-01
Completion
2022-07-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429450 on ClinicalTrials.gov